Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Which Is the Best COVID Vaccine Stock Now: Pfizer, BioNTech, or Moderna?

By Keith Speights - Dec 15, 2020 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: There isn't just one answer.

Pfizer ( PFE 2.54% ) and BioNTech ( BNTX -2.97% ) recently won U.S. emergency use authorization (EUA) for their COVID-19 vaccine. An EUA for Moderna's ( MRNA -4.36% ) vaccine could be only days away. In this Motley Fool Live video recorded on Dec. 9, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss which of these stocks is the best pick for investors right now.

Corinne Cardina: From an investment standpoint, which of the three stocks that we are discussing that are a hair away from the finish line: Pfizer, BioNTech, and Moderna -- which do you think is the better buy today?

Keith Speights: [laughs] Let me say this. I think all three of these stocks still have upside potential. Not everything is baked into the share prices, even though Moderna, for example, has really skyrocketed this year. But I think all of them have some degree of upside potential.

I do think that more conservative investors would like Pfizer out of these three. Pfizer, of course, has been around for, I guess, around 150 years or so, and they're a successful company over the long term. They have lots of other blockbuster products already on the market, other growth drivers. Their COVID vaccine is obviously a big plus for Pfizer, but it's not the only arrow in the company's quiver. I think conservative investors would really like Pfizer because of its stability, its financial strength, its dividend, and its growth prospects.

Over the long run, if I had to guess, I would say probably Moderna may have the potential to be the biggest winner, just because it could be a platform kind of stock. The company has always thought that if the mRNA approach works with one disease, it could work with a lot of diseases.

Moderna already has about a dozen pipeline candidates. Their CEO has said that when the money starts rolling in, assuming it does from their COVID vaccine mRNA 1273, that they plan to really beef up their pipeline and potentially expand it to up to 50 programs in clinical testing. That could pay off big time over the next decade or so. I think Moderna still has potential, even though a lot of its growth for the COVID vaccine is already baked into the price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$352.43 (-4.36%) $-16.08
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.73 (2.54%) $1.33
BioNTech SE Stock Quote
BioNTech SE
BNTX
$351.74 (-2.97%) $-10.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.